CAR-T therapy for neuroblastoma targeting three markers
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must test positive for at least one of the three markers: GD2, PSMA, or CD276.
- You must have had standard treatment for neuroblastoma, and the cancer is still growing or has spread.
- Your general health must be fairly good (Karnofsky or Lansky score of 60% or higher).
- Your heart, lungs, liver, and kidneys must be working well enough based on standard tests.
- You must not have untreated brain tumors or active infections like HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.